Phase 2 study of weekly irinotecan in adults with recurrent malignant glioma: Final report of NABTT 97-11
Open Access
- 1 January 2004
- journal article
- clinical trial
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 6 (1) , 21-27
- https://doi.org/10.1215/s1152851703000218
Abstract
The primary objective of this study was to determine the proportion of patients exhibiting a radiographic response in a cohort of patients with recurKeywords
This publication has 19 references indexed in Scilit:
- Enhancement of irinotecan (CPT-11) activity against central nervous system tumor xenografts by alkylating agentsCancer Chemotherapy and Pharmacology, 1998
- Modulation of glucuronidation of SN-38, the active metabolite of irinotecan, by valproic acid and phenobarbitalCancer Chemotherapy and Pharmacology, 1997
- Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against pediatric and adult central nervous system tumor xenograftsCancer Chemotherapy and Pharmacology, 1996
- IRINOTECAN (CPT‐11): A BRIEF OVERVIEWClinical and Experimental Pharmacology and Physiology, 1996
- Rationale for the dosage and schedule of CPT-11 (irinotecan) selected for phase II studies, as determined by European phase I studiesAnnals of Oncology, 1996
- The clinical status of irinotecan (CPT-11), a novel water soluble camptothecin analogue: 1996Critical Reviews in Oncology/Hematology, 1996
- Irinotecan (CPT-11): pharmacology and clinical applicationsCritical Reviews in Oncology/Hematology, 1996
- Characterisation and Clinical Management of CPT-11 (Irinotecan)-induced Adverse Events: The European PerspectiveEuropean Journal Of Cancer, 1996
- Quantitative analysis of DNA topoisomerase I activity in human and rat glioma: Characterization and mechanism of resistance to antitopoisomerase chemical, camptothecin-11Journal of Surgical Oncology, 1993
- Optimal two-stage designs for phase II clinical trialsControlled Clinical Trials, 1989